Gossamer Bio: Seralutinib Meets Primary Endpoint In Phase 2 Study In Pulmonary Arterial Hypertension
Gossamer Bio, Inc. (GOSS) reported topline results for the TORREY Phase 2 study of seralutinib in patients with pulmonary arterial hypertension. In the study, seralutinib significantly improved hemodynamic, biomarker, and right heart structural and functional measures in a heavily treated PAH patient population. Seralutinib was generally well tolerated in the TORREY study.
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology.
For More Such Health News, visit rttnews.com.
Couchbase, Inc. Q3 Loss Beats Estimates
Couchbase, Inc. (BASE) released Loss for third quarter that missed the Street estimates.
The company’s earnings totaled -$16.677 million, or -$0.37 per share. This compares with -$15.924 million, or -$0.37 per share, in last year’s third quarter.
Excluding items, Couchbase, Inc. reported adjusted earnings of -$9.714 million or -$0.22 per share for the period.
Analysts on average had expected the company to earn -$0.33 per share, according to figures compiled by Thomson Reuters. Analysts’ estimates typically exclude special items.
The company’s revenue for the quarter rose 25.1% to $38.557 million from $30.824 million last year.
Couchbase, Inc. earnings at a glance (GAAP) :
-Earnings (Q3): -$16.677 Mln. vs. -$15.924 Mln. last year.
-EPS (Q3): -$0.37 vs. -$0.37 last year.
-Analyst Estimates: -$0.33
-Revenue (Q3): $38.557 Mln vs. $30.824 Mln last year.
Next quarter revenue guidance: $38.2Mln- $38.4Mln
Full year revenue guidance: $151.4Mln- $151.6Mln
Barnes & Noble Education, Inc. Q2 sales decline
Barnes & Noble Education, Inc. (BNED) revealed a profit for second quarter of $22.144 million
The company’s earnings came in at $22.144 million, or $0.42 per share. This compares with $22.528 million, or $0.41 per share, in last year’s second quarter.
The company’s revenue for the quarter fell 1.6% to $617.098 million from $626.977 million last year.
Barnes & Noble Education, Inc. earnings at a glance (GAAP) :
-Earnings (Q2): $22.144 Mln. vs. $22.528 Mln. last year.
-EPS (Q2): $0.42 vs. $0.41 last year.
-Revenue (Q2): $617.098 Mln vs. $626.977 Mln last year.
NRG Energy To Acquire Vivint Smart Home For $2.8 Bln In Cash
NRG Energy, Inc. (NRG) and Vivint Smart Home, Inc. (VVNT) announced Monday they have entered into a definitive agreement under which NRG will acquire Vivint for $12 per share or $2.8 billion in an all-cash transaction. The agreement has been unanimously approved by the boards of directors of both companies.
Vivint Smart Home is a leading smart home platform company that provides technology, products, and services to create a smarter, more efficient, and safer home.
The acquisition accelerates the realization of NRG’s consumer-focused growth strategy and creates the leading essential home services platform fueled by market-leading brands, unparalleled insights, proprietary technologies, and complementary sales channels.
The transaction improves and diversifies NRG’s financial profile while also expanding the total market opportunity available to NRG. The annual run-rate adjusted EBITDA, inclusive of $100 million of run-rate synergies, is $835 million.
NRG will acquire 100% of the outstanding equity of Vivint for a total transaction value of $5.2 billion, which consists of approximately $2.8 billion in cash and the assumption of $2.4 billion of debt (net of cash).
This consideration represents a premium of approximately 33% to Vivint’s closing share price on December 5, 2022.
The transaction is expected to close in the first quarter of 2023 and is subject to customary closing conditions. Upon completion of the transaction, NRG intends to maintain a significant presence in Utah.
AutoZone Q1 Results Top Estimates
Automotive replacement parts retailer AutoZone, Inc. (AZO) reported Tuesday that net income for the first quarter decreased to $539.32 million or $27.45 per share from $555.24 million or $25.69 per share in the year-ago quarter.
Net sales for the quarter grew 8.6 percent to $3.99 billion from $3.67 billion in the same quarter last year.
On average, analysts polled by Thomson Reuters expected the company to report earnings of $25.27 per share on revenues of $3.86 billion for the quarter. Analysts’ estimates typically exclude special items.
Domestic same store sales, or sales for stores open at least one year, increased 5.6 percent for the quarter.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
Kroger Says Will Work Cooperatively With The FTC On Second Request On Albertsons Merger
The Kroger Co. (KR) said on Tuesday it has received a request for additional information (second request) from the Federal Trade Commission or FTC as part of the regulatory review process for its merger with Albertsons Companies, Inc. (ACI).
Kroger said it will continue to work cooperatively with the FTC as it conducts its review of the merger, including developing a thoughtful divestiture plan. Kroger continues to expect to complete the merger in early 2024, subject to customary closing conditions.
The second request extends the waiting period imposed by the Hart-Scott-Rodino Antitrust Improvements Act until 30 days after Kroger and Albertsons Cos. have substantially complied with the requests or the waiting period is terminated sooner by the FTC.
Gerresheimer AG Increases Its Revenue, Adj. EBITDA Guidance – Quick Facts
Gerresheimer AG (GRRMF.PK) reaffirmed its growth agenda and increased its revenue and adjusted EBITDA guidance. The guidance for fiscal 2023, for group level, FXN, include: organic revenue growth: at least 10%; organic adjusted EBITDA growth: at least 10%; and adjusted EPS growth: low-single digit.
For mid-term, for group level, FXN, guidance includes: organic revenue growth: at least 10%; organic adjusted EBITDA margin: of 23-25%; and adjusted EPS growth: at least 10%.
Dietmar Siemssen, CEO of Gerresheimer AG, said: “Our formula g strategy process is paying off and generating sustainable growth across all our divisions. With new orders for High Value Solutions and Medical Devices, we have further reinforced our leading positions in attractive markets. We will continue to shift the portfolio from volume to value and expand our margins.”
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.